provenge
dendreon uk ltd - autologne mononuklearne stanice periferne krvi, uključujući najmanje 50 milijuna autolognih cd54 + stanica koje su aktivirane s fosfatazom prostate kiseline granulocitno-makrofagskog faktora koji stimulira kolonije - prostatske neoplazme - ostali imunostimulanti - provenge je indiciran za liječenje asimptomatski ili minimalno simptomatsko metastatski (sobe-visceralni) kastrirati otporna karcinoma prostate u odraslih muškaraca u kojih kemoterapija nije još klinički indiciran.
ceftazidim hospira 1 g prašak za otopinu za injekciju/infuziju
hospira uk ltd., queensway, royal leamington spa, warwickshire, ujedinjeno kraljevstvo - ceftazidimum - prašak za otopinu za injekciju/infuziju - 1 g - urbroj: svaka bočica sadrži 1,165 g ceftazidim pentahidrata, što odgovara 1 g ceftazidima
ceftazidim hospira 2 g prašak za otopinu za injekciju/infuziju
hospira uk ltd., queensway, royal leamington spa, warwickshire, ujedinjeno kraljevstvo - ceftazidimum - prašak za otopinu za injekciju/infuziju - 2 g - urbroj: svaka bočica sadrži 2,330 g ceftazidim pentahidrata, što odgovara 2 g ceftazidima
natlinez 2 mg/ml otopina za infuziju
hospira uk ltd., queensway, royal leamington spa, warwickshire, velika britanija - linezolidum - otopina za infuziju - 2 mg/ml - urbroj: 1 ml otopine za infuziju sadrži 2 mg linezolida
propofol hospira 10 mg/ml emulzija za injekciju/infuziju
hospira uk ltd., queensway, royal leamington spa, warwickshire, velika britanija - propofolum - emulzija za injekciju ili infuziju - 10 mg/ml - urbroj: 1 ml emulzije za injekciju/infuziju sadrži 10 mg propofola
symkevi
vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.
nityr
cycle pharmaceuticals (europe) ltd - nitisinone - tyrosinemias - drugi gastrointestinalni trakt i metabolizam, lijekovi, - liječenje i pedijatrijski bolesne odrasle osobe s potvrđene dijagnoze nasljedne тирозинемии 1 (ХТ-1) u kombinaciji s prehrambenim ograničenjima tirozin i fenilalanin.
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
vazkepa
amarin pharmaceuticals ireland limited - icosapent ethyl - dislipidemije - sredstva za modifikaciju lipida - indicated to reduce cardiovascular risk as an adjunct to statin therapy.
pedmarqsi
fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - svi ostali terapeutski proizvodi - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.